Details of the Drug

General Information of Drug (ID: DM1ZY6M)

Drug Name
227Th-labelled MSLN-TTC
Synonyms BAY2287411
Indication
Disease Entry ICD 11 Status REF
Epithelioid mesothelioma 2F10 Phase 1 [1]
Drug Type
Radiopharmaceutical therapy agent
Cross-matching ID
TTD ID
DJ25DI

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Mesothelin (MSLN) TT4RXME MSLN_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Epithelioid mesothelioma
ICD Disease Classification 2F10
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Mesothelin (MSLN) DTT MSLN 2.86E-20 3.98 6.12
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03507452) First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin. U.S. National Institutes of Health.
2 Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers. Clin Cancer Res. 2019 Aug 1;25(15):4723-4734.